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Abstract 
Hypoxic-ischaemic encephalopathy, resulting from asphyxia during birth, affects 2-3 in every 1000 
term infants and depending on severity, brings about life-changing neurological consequences or 
death. This hypoxic-ischaemia (HI) results in a delayed neural energy failure during which the majority 
of brain injury occurs. Currently, there are limited treatment options and additional therapies are 
urgently required. Mitochondrial dysfunction acts as a focal point in injury development in the 
immature brain. Not only do mitochondria become permeabilised, but recent findings implicate 
perturbations in mitochondrial dynamics (fission, fusion), mitophagy and biogenesis. Mitoprotective 
therapies may therefore offer a new avenue of intervention for babies who suffer life-long disabilities 




Moderate to severe hypoxic-ischaemic encephalopathy (HIE), caused by birth asphyxia in term or 
near-term babies, affects 1-2 in every 1000 live births in the UK and far more in the developing world 
[1-3]. The consequences for babies and parents affected by HIE are devastating; 15-20% of infants will 
die in the postnatal period and a further 25% will develop severe and long-lasting neurological 
impairments presenting significant emotional and financial burdens [4]. Currently, therapeutic 
hypothermia is the only mandated therapy approved for term HIE which, when initiated within the 
first 6h of birth, doubles the chance of survival without neurocognitive defects [5-8]. However, the 
number needed to treat for an improvement is 7 – 8 infants [5, 7] highlighting the urgent need for 
synergistic, additive treatments. Crucially, though, therapeutic hypothermia provides proof-of-
concept for neuroprotective intervention post-injury and represents the first evidence-based therapy 
for term HI [5-7, 9-13].  
 
We and others have shown that HI triggers a broad spectrum of signalling events [14-17] culminating 
in cell death characterized morphologically by a mixed necrotic/necroptotic-apoptotic phenotype [15, 
18-20]. However, data from our lab and others strongly suggest that mitochondrial dysfunction acts 
as a hub for these diverse injury responses [18, 21, 22]. Mitochondrial permeabilisation, electron 
transport impairment reducing ATP generation, production of ROS, apoptosis and cell death are all 
key elements of the evolution of injury in the neonatal brain, and both mitochondria and anti-oxidant 
defence systems are more vulnerable in the neonatal brain than the adult brain [21]. More recently, 
perturbation of mitochondrial dynamics (fission, fusion) and mitophagy have also been described in 
the immature brain after insult. Therefore interventions designed to protect mitochondrial function 
in the hours following hypoxia-ischemia should thus safeguard neuronal survival, providing additional 
neuroprotection for infants where hypothermia alone is inadequate. 
 
Mitochondria act as hubs for development of brain injury  
Phases of neonatal brain injury 
Clinical MRI studies report that encephalopathy following perinatal asphyxia and/or hypoxia-
ischaemia (HI) in the term neonate is characterized predominantly by lesions in grey matter structures 
such as the thalamus and basal ganglia, additional cortical abnormalities and associated white matter 
[23-25]. In near-term and term neonates (>36 weeks) it is predominantly neurons that are most 
vulnerable to injury and death, with the extent of lesion size being strongly associated with the 
severity of long-term impairments [26]. During the primary phase of injury, restricted cerebral blood 
 4 
 
flow reduces oxygen and glucose delivery causing a switch to anaerobic respiration, reducing 
phosphocreatine and ATP, and increasing lactic acid production [27, 28]. Reperfusion enables a latent 
phase to occur and there is a transient recovery of ATP reserves to almost physiological levels 
providing a treatment window between 1 and 6 hours following injury [29]. However, a secondary 
phase of rapid energy failure follows [30-32] which lasts from hours to days, during which neuronal 
cell death occurs. Numerous rodent studies demonstrate that preventing this delayed cell death phase 
offers significant long-term neuroprotection [33-36]. If intervention is unsuccessful, a tertiary phase 
of injury is initiated which lasts from weeks to years, and which is dependent on persistent 
inflammation and epigenetic modifications [37].  
Mitochondrial dysfunction in HIE 
The molecular consequences of HI injury are many and varied, but a common target of this metabolic 
dysfunction is mitochondrial impairment [21]. The initial depletion of high energy phosphates results 
in membrane transporter deficits leading to accumulation of sodium and calcium within the cell, 
subsequent depolarisation and release of excitotoxic levels of glutamate [14, 38]. The activation of 
glutamatergic AMPA and NMDA receptors perpetuates the influx of calcium into the neuron which 
accumulates within the endoplasmic reticulum and the mitochondrial matrix (Figure 1). Mitochondria 
in the immature brain are less efficient at buffering calcium and this influx leads to mitochondrial 
swelling within 30 min – 3h of the original insult, triggering calcium-activated proteases and lipases 
[15]. Calmodulin-dependent activation of nitric oxide synthase generates nitric oxide which in turn 
results in the blockage of mitochondrial respiratory complex IV and formation of peroxynitrites [39]. 
Additionally, although the direct mechanisms of mitochondrial calcium-mediated ROS production are 
still unclear [40], calcium overload coincides with upregulated superoxide production due to electron 
leakage from complexes I and III of the electron transport chain (Figure 1). The accumulation of 
hydroxyl and peroxynitrite radicals leads to lipid peroxidation, protein nitrosylation and DNA damage 
which is more acute in the immature brain given its limited antioxidant capacity and free availability 
of catalytic iron [39].  
Mitochondria are also susceptible to permeabilisation after neonatal HI injury [41]. In the immature 
brain, this has been identified as mitochondrial outer membrane permeabilisation (MOMP; Figure 1) 
in contrast to formation of the mitochondrial permeability transition pore where both inner and outer 
membranes are opened [42]. MOMP is mediated by the balance of pro- and anti-apoptotic members 
of the Bcl-2 family. When anti-apoptotic proteins Bcl-2, Bcl-xL and MCL1 lift their inhibition of 
proapoptotic Bax it becomes activated and translocates to the outer mitochondrial membrane (OMM) 
where it oligomerises and forms pores [43]. Similarly, mitochondrial pores can be formed with another 
family member, Bak, already localised at the OMM [44].  HI-mediated activation of upstream enzymes 
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such as caspase-2 and p53 can also target proapoptotic Bcl-2 proteins such as Bid, Noxa and PUMA 
resulting in Bax-mediated MOMP (Figure 1; [35, 45, 46]). We and others have shown that 
pharmacological or genetic inhibition of p53, Bax and caspase-2 results in attenuation of the injury 
process and a reduction in infarct volume in a well characterised rodent model of neonatal HI [35, 36, 
45, 47-49]. In particular, brain injury is significantly reduced in Bax knockout mice or after treatment 
with Bax inhibitory peptide reaffirming that in the immature brain, Bax-dependent MOMP plays a 
critical role in neuronal cell death [36, 42]. 
Once permeabilised, components of the apoptotic cascade are leaked into the cytosol including 
cytochrome c, apoptosis-inducing factor (AIF), endonuclease G and SMAC/Diablo [50]. Cytosolic 
cytochrome c and Apaf-1 combine to form the apoptosome, recruiting and activating caspase-9 and 
subsequently activating caspase-3, a process enhanced by SMAC/Diablo (Figure 1). Active caspase-3 
cleaves Caspase-activated DNase (CAD) inhibitors thus leading to CAD activation and chromatin 
fragmentation occurs [44]. In parallel, caspase-independent cell death is also triggered through the 
mitochondrial release of AIF and Endo G which translocate to the nucleus and result in chromatin 
fragmentation (Figure 1). It is worth noting that due to rapid brain development, caspase-dependent 
and independent mechanisms are more critical in the immature brain than the adult brain [51, 52] 
and expression of key proteins is markedly upregulated. Furthermore recent studies have identified 
new regulators of these apoptotic pathways which are specifically perturbed after neonatal HI injury 
in a rodent model. CHCHD4 is an AIF-interacting protein implicated in protein import and Ca2+ uptake. 
Genetic CHCHD4 haploinsufficiency resulted in reduced infarct size and a reduction in caspase-
independent neuronal cell death [53]. Severe HI insult in vivo also results in the loss of the AIF negative 
regulatory protein Iduna, exacerbating the injury as well as contributing to the development of 
neurocognitive impairment [54, 55]. 
  
Mitochondria in perinatal inflammation  
Inflammation is an important risk factor for injury in the developing brain [56]. Mitochondria act as 
central hubs in the innate immune system by regulating receptors, including RIG-I-like receptors 
(RLRs), NOD-like receptors (NLRs) and Toll-like receptors (TLR) [57]. As mitochondria are the nexus of 
metabolic pathways, current evidence supports the hypothesis that mitochondrial metabolism 
controls functions and fate of immune cells [58], including regulation of cytokine or chemokine 
responses [59, 60]. Our recent data shows that inflammation-induced suppression of mitochondrial 
respiration may contribute to increased susceptibility to HI injury in the neonatal brain [61]. However, 
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the connection between mitochondrial function, inflammation, and energy metabolism in cerebral 
immune cells is not well characterized. 
Microglia, the immune cells of the brain, orchestrate the inflammatory response to diverse insults, 
and these cells can have both beneficial and detrimental effects on the brain that may be linked to 
mitochondrial function. A short exposure of a low dose of lipopolysaccharide (LPS) causes a transient 
increase in oxidative phosphorylation (OXPHOS) in microglia, whereas a prolonged exposure to high 
dose LPS causes suppression of OXPHOS and mitochondrial respiration. The suppression of OXPHOS 
forces a shift in metabolism towards glycolysis to meet cellular energy demand and an increased pro-
inflammatory cytokine profile. Other mechanisms by which mitochondria influence immune cell fate 
decisions include mitochondrial ROS and generation of TCA cycle metabolites that control epigenetic 
modifications. Mitochondrial ROS diffuse into the cytoplasm and modulate transcription factors, such 
as hypoxia-inducible factor 1α (HIF1α), nuclear factor of activated T cells (NFAT) and nuclear factor-κB 
(NF-κB), promoting inflammatory gene expression [62]. Transcriptional changes also lead to altered 
TCA cycle metabolites such as α-ketoglutarate and succinate, which are substrates and products of 
histone demethylases [63].  Similarly, sirtuin lysine deacetylases responding to the ratio of NAD/NADH 
have been implicated in the regulation of metabolism by histone demethylation [64]. 
Injured mitochondria release extracellular mitochondrial DNA (mtDNA), which can act as damage-
associated molecular pattern (DAMP) molecules and induce inflammation in response to non-
infectious injury [65]. It has been reported that DAMPs serve as ‘Signal 0s’ that binds to innate immune 
receptors to promote autophagy termed ‘immunophagy’ [66, 67]. Mounting evidence shows that 
selective autophagy or mitophagy regulates innate immune responses primarily by maintaining a 
functional cohort of mitochondria within the cell to prevent damaging levels of activation [68]. 
Oxidized mtDNA released into the cytosol binds to NLRP3 resulting in activation and caspase-1 
maturation [69], which in turn can induce an inflammatory form of cell death referred to as pyroptosis 
and disruption of glycolytic flux [70, 71]. Further, when released from necrotic cells, mitochondrial 
transcription factor A (Tfam) can also act as a specific DAMP causing  pro-inflammatory and cytotoxic 
responses through lysosomal dysfunction in T cells [72] [73]. 
Mitochondrial Dynamics 
Although evidence implicating mitochondria as the hub of the injury response after HI has centred on 
identification of the mechanisms leading to MOMP [21], recent studies suggests that dynamics are 
also targeted by HI. Mitochondrial morphology and function is regulated by a cycle of fission and 
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fusion, coupled with mitophagy (mitochondrial recycling) and biogenesis which maintain 
mitochondrial integrity and health (Figure 2).  
Fission and Fusion 
Mitochondria undergo continuous fission and fusion through highly regulated processes in response 
to metabolic demands, ensuring energy requirements are met [21, 74, 75]. Fission is required for cell 
division, biogenesis and quality control whereas fusion upregulates ATP production as well as ensuring 
the mixing of mitochondrial contents [74, 76]. In response to stress, low levels of mitochondrial 
damage can also be corrected by fusion, creating a larger mitochondrion with greater buffering 
capacity [74]. It is therefore unsurprising that perturbations in the regulation of fission and fusion are 
implicated in the development of pathologies including numerous neurodegenerative diseases [77], 
cancer [78], cardiovascular disease [79], obesity and diabetes [80].  
During early postnatal life, there is a substantial metabolic demand in the brain and a significant 
increase in mitochondrial number is observed. This early period is coupled with neuronal development 
and the subsequent high demand for energy to maintain homeostasis sensitises the brain to injury 
following dysfunctional mitochondria (reviewed in [21]). The importance of faithful fission and fusion 
in neurons cannot be underestimated as defects in fusion result in early onset conditions such as 
Dominant Optic Atrophy and Charcot Marie Tooth disease type 2A [74]. 
The processes of fission and fusion are regulated by members of the GTPase Dynamin family. Fission 
is triggered through Drp1 and fusion through Mfn1/2 (outer mitochondrial membrane fusion) and 
OPA1 (inner mitochondrial membrane fusion) [74, 81-84]. Both fission and fusion proteins are 
regulated through proteolysis and posttranslational modifications [74]. Ultimately, an effective fission 
and fusion cycle allows separation of dysfunctional and functional mitochondria, enabling selective 
removal by mitophagy, leaving a functional mitochondrial network behind to aid cellular recovery [85]. 
Fission  
Drp1 originates from nuclear DNA and following translation, remains cytosolic [82, 86, 87], undergoing 
posttranslational modification, including phosphorylation prior to recruitment to the mitochondria 
[87]. Although contact with the endoplasmic reticulum is believed to designate the fission point on 
the mitochondrion [88], Drp1 is essential for the fission process, inducing fission via its GTPase activity 
following self-assembly [89]. Drp1 is maintained in its cytosolic location through scaffolding in a 
complex with AKAP which facilitates its phosphorylation at Ser 637 by protein kinase A (PKA) and 
inhibits its GTPase activity [90]. Upon dephosphorylation by calcineurin [91] or PP2A [92] and 
rephosphorylation at Ser 616 by cdk1, Drp1 translocates to the mitochondrion and binds to one of a 
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number of OMM-localised receptors including Fis1, Mff, MiD49 and MiD51 [86, 93]. The interaction 
between one of these membrane-anchored proteins and Drp1 is essential for the fission process, 
however, the specific mechanism of recruitment is still unclear [87]. Although Fis1 was the first 
mitochondrial receptor to be identified for Drp1 [94, 95], recent evidence supports Mff as mediating 
the majority of Drp1 interactions [96]; overexpression of Mff lead to excessive mitochondrial 
fragmentation [86]. At the mitochondrial membrane, Drp1 spirals around mitochondria forming a 
helical structure and causing GTP-driven constriction [89] which results in severing of both the outer 
and inner mitochondrial membranes [21, 74]. Additional regulation of the mitochondrial recruitment 
of Drp1 was recently identified through its trimolecular interaction with Mff and MiD49/51. High 
expression levels of MiD49/51 results in suppression of fission, whereas lower levels of MiD49/51 
promote fission [86].  
Fusion  
Fusion is governed by the co-operative action of Mfn1 and Mfn2 at the OMM and OPA1 at the IMM. 
At the OMM, interactions between Mfn1 & Mfn2 link adjacent mitochondria together and allow GTP-
mediated fusion of the outer mitochondrial membrane [97]. Both proteins are required during early 
development as Mfn1 & Mfn2 single knock-out mice die before birth and the double knock-out mice 
die mid gestation due to insufficient mitochondrial fusion in the placenta [98]. Both Mfn1 and Mfn2 
are capable of regulating OMM fusion, although Mfn1 is more efficient than Mfn2 and is required for 
efficient OPA1 function [99, 100]. Mfn2 is also reported to be located in the endoplasmic reticulum 
(ER) membrane and can therefore facilitate ER-mitochondrial interactions, although aspects of this 
tethering remain unclear [101, 102]. However, the structural and functional similarity between them 
enables each Mfn to be capable of partially compensating for loss of the other [98]. 
OPA1 is located on the inner mitochondrial membrane and can exist as eight isoforms in humans, due 
to alternate splicing of exons 4, 4b and 5 [103, 104]. Efficient IMM fusion requires a combination of 
long and short forms of OPA1 which are generated through proteolytic cleavage at the ubiquitous S1 
site or the variant-dependent S2 site [104, 105]. OPA1 cleavage occurs due to the actions of the ATP-
dependent i-AAA-protease Yme1L and the ATP-independent zinc-metalloprotease Oma1 [106, 107].  
Yme1L cleaves OPA1 at the S2 site, and the subsequent mix of long, membrane-bound OPA1 and short, 
soluble OPA1 is optimal for OPA1 function [105, 108]. However, loss of mitochondrial membrane 
potential results in Oma1-mediated cleavage of OPA1 at the S1 site generating excess short forms of 
OPA1 and rendering the mitochondrion fusion-incompetent [106, 107].  
As mentioned earlier, Bax-mediated MOMP and subsequent cytochrome c release is pivotal in the 
development of neonatal brain injury in response to HI insult [18, 35, 109, 110]. However, the majority 
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of cytochrome c is held within the cristae, relying on cristae remodelling to allow it access to move 
into the intermembrane space once apoptosis is triggered. Not only is OPA1 critical for IMM fusion, 
but it is also necessary for maintaining stable cristae junctions [111, 112] and for efficient function of 
the respiratory complexes of the electron transport chain [113].  Inhibition of OPA1 leads to cristae 
disorganization [114] and a number of studies have highlighted that this cristae remodelling is 
triggered by Bcl2 family members such as Bax, Bim and t-Bid [112, 115, 116].  A recent study proposes 
that Bax/Bak oligomerisation at the mitochondrial membrane can act as a trigger for Oma1 activation 
[117]. The authors also suggest that induction of tBid may also play a role in the activation of Oma1, 
and speculate that in order for these actions to occur, there needs to be interaction between Bax/Bak 
oligomers and the contact points for inner and outer mitochondrial membranes.  
Mitochondrial dynamics and neonatal brain injury 
The impact of HI injury on mitochondrial dynamics in the immature brain has been determined 
experimentally in vitro using oxygen-glucose deprivation (OGD) in primary neurons as well as in vivo 
using a well characterised rodent model of neonatal hypoxic-ischaemic brain injury. In vitro, OGD 
results in a rapid induction of fission in primary neurons [75, 118] coinciding with the pathological 
cleavage of OPA1 into short fusion-incompetent forms. This degradation of long OPA1 was mirrored 
in vivo at 24h after induction of HI injury [118]. Inhibition of Drp1 expression by siRNA (and thus 
maintenance of fusion) in hippocampal cells provided protection after OGD and glutamate 
excitotoxicity [119]. While there are a number of studies examining mitochondrial morphology in the 
adult brain after ischaemic injury [120], there are currently few in vivo studies of the immature brain 
after HI. However, Demarest and colleagues [121] recently quantified brain mitochondrial size after 
neonatal HI in immature rats and found that there was a rapid induction of mitochondrial 
fragmentation. Interestingly, this study identified sex-specific differences with the degree of fission in 
the injured hemisphere being more marked in males than females [121].  
Mitochondrial dynamics are also impacted in response to immune challenge in the immature brain. 
As well as inducing metabolic reprogramming, LPS treatment (100ng/ml) results in excessive 
mitochondrial fission in primary microglia [122]. Both the fission phonotype and the LPS-induced 
metabolic switch can be prevented by treatment with an inhibitor of fission. Therefore, altering 
mitochondrial dynamics can be a therapeutic modality for preventing neuroinflammation-induced 





Mitophagy - mitochondrial quality control 
Mitochondrial mitophagy is defined as the selective degradation (or selective autophagy) of 
sufficiently damaged mitochondria through an autophagosomal-lysosomal pathway [123]. The most 
well characterised mechanism triggering mitophagy relies on PTEN-induced putative kinase 1 (PINK1) 
/ Parkin [4, 5]. The importance of mitophagy is underlined by the availability of additional pathways 
to mitochondrial recycling including the BNIP3, NIX and FUNDC1 ([124]; Figure 3). Once mitophagy is 
triggered, mitochondrial-localised receptors bind LC3B (Figure 3), a microtubule-associated protein 
converted from LC3A through conjugation with phophatidylethanolamine. This conversion allows 
LC3B to relocate from the cytosol into phagophore membranes thus linking the damaged 
mitochondrion with the vesicle mediating its degradation (Figure 2, [125]).  
PINK1 and Parkin 
PINK1 is a serine/threonine kinase targeted to mitochondria via its N terminal signal sequence. It is 
imported into the IMM in healthy mitochondria in the presence of a high mitochondrial membrane 
potential (ΔΨm) [124, 126]. However, once there, PINK1 is degraded by matrix processing peptidase 
(MPP) and presenilin-associated rhomboid-like (PARL)[124]. Conversely, upon cellular insult resulting 
in mitochondrial depolarisation, import of PINK1 to the inner mitochondrial membrane is inhibited 
and it subsequently accumulates on the outer mitochondrial membrane [126]. PINK1 then 
phosphorylates ubiquitin (at Ser 65) resident on OMM proteins [127, 128], recruiting the E3 ubiquitin 
ligase Parkin to bind to the phospho-ubiquitin [129]. As Parkin itself contains a ubiquitin-like domain, 
it becomes a substrate for PINK1 phosphorylation, enabling an increased, Parkin-mediated ligation of 
ubiquitin to proteins on the OMM, thus increasing substrate availability for PINK1 [130]. Adaptor 
proteins (SQSTM/p62, optineurin, NDP-52 etc.; [131]; Figure 3A) are recruited which lead to binding 
of LC3B and engulfment of the dysfunctional mitochondrion by an autophagosome which, when fused 
with a lysosome, promotes degradation of its contents. This mechanism allows for the selective 
degradation of a damaged mitochondrion and impairment is thought to play a key role in Parkinson’s 
disease as well as ageing in general.  It is worth highlighting that mechanisms of PINK1/Parkin 
mitophagy have largely been elucidated in vitro and utilising mitochondrial toxins targeting large 
populations of mitochondria in order to instigate mitophagy. There still remains a number of questions 
about mechanisms triggered in vivo in response to discrete mitochondrial dysfunction [132].   
BNIP3 and NIX 
Other PINK1-independent mechanisms of mitophagy have also been identified. Bcl-2 and adenovirus 
E1B 19 kDa interacting protein 3 (BNIP3) and BNIP3-like (BNIP3L), also known as NIX, are single pass 
transmembrane receptors localised to the outer mitochondrial membrane which are capable of 
recruiting LC3B (Figure 3B). As BNIP3 expression is regulated by HIF1-α expression, it becomes 
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activated in response to hypoxia and has been implicated in mitophagy in response to stroke [133]. 
Both BNIP3 and NIX are implicated in Bax-mediated cell death with hypoxia-activated Bnip3 and 
excitotoxicity-activated Nix resulting in Bax and Bak signalling [134, 135]. BNIP3 also links fission and 
mitophagy as there is a requirement for Drp1 (as well as Parkin) for mitophagy in cardiomyocytes 
[136].  
FUNDC1 
FUNDC1 is mitochondrial outer membrane protein, which binds LC3B directly in response to hypoxia 
(Figure 3C; [137, 138]). FUNDC1 and LC3B becomes stabilised under hypoxic conditions, which is 
attributed to dephosphorylation of FUNDC1 at Tyr18 during hypoxia. Indeed, Src kinase inhibits 
FUNDC1-mediated mitophagy in response to hypoxia [137].  FUNDC1 is also negatively regulated by 
ser13 phosphorylation by casein kinase 2 which can be counteracted by the action of PGAM5-
mediated dephosphorylation in response to a hypoxia cue [139]. Conversely, PGAM5 can be inhibited 
by interaction with Bcl-xL (but not Bcl-2) thus providing a regulatory signalling loop dependent on the 
cellular stress [140].  
Mitophagy and neonatal brain injury 
The role of mitophagy in the development of neonatal brain injury after HI is still unclear and it remains 
to be determined whether induction of mitophagy post injury would be beneficial or deleterious. 
Current evidence is circumstantial as it is based mainly on modulating components of the autophagy 
pathway rather than mitophagy directly. For example, in an in vitro hippocampal slice culture model 
of immature brain, cell death as a result of exposure to OGD was significantly reduced when the slices 
were pre-treated with a pharmacological inhibitor of autophagy, 3-methyladenine (3-MA; [141]). In 
vivo, 3-MA inhibition prior to HI prevented increased LC3B expression in neonatal rats as well as 
reducing memory impairment in subsequent behavioural tests [142]. In line with this observation, 
neonatal HI-induced brain injury in mice lacking a protein critical for autophagosome formation (Atg7-
/-) was significantly reduced compared with WT litter mates [143]. However, more specifically, BNIP3 
was shown to co-localise with LC3B in mice after neonatal HI in vivo and OGD in vivo, and infarct 
volume and cell death were prevented when BNIP3 expression was genetically ablated [133]. Bnip3 
gene expression was also upregulated in neonatal rat brain in a study examining the effects of hypoxic 
preconditioning, a sublethal insult which is known to induce subsequent neuroprotection after HI 
injury [144]. Mitochondrial and lysosomal co-localisation were also observed in immature rat brain 
but in this study there were marked sex-specific differences, with greater induction of mitophagy in 
females versus males [121] echoing previous observations of increased basal autophagy and 
upregulated LC3B expression in female rats after neonatal HI [145].  As brain injury in males was more 
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severe, these data contradict studies mentioned earlier which suggested that inhibition of autophagy/ 
mitophagy may confer protection.   
 
Biogenesis 
Biogenesis is required for the increase in mitochondrial mass within a cell and is dependent on both 
fission of existing mitochondria followed by a co-ordinated programme of transcription and 
translation principally regulated by the transcription factor PGC-1α [146]. This process is crucial to 
allow for growth and recovery of the existing mitochondrial network following depletion by mitophagy 
[147]. Ultimately, this process ensures the mitochondrial network is able to efficiently support and 
adapt to the metabolic needs of the cell [147]. The whole process is carefully orchestrated, involving 
synthesis driven by both mitochondrial and nuclear DNA and coordinated import of around 1000 lipids 
and proteins [21, 146, 147]. 
PGC-1α is widely considered the master regulator and is often upregulated during times when the 
demand to energy is increased [147, 148]. PGC-1α is often expressed at high levels within neurons and 
due to their inherent high demand for energy [146, 148]. PCG-1α is unable to bind DNA directly, 
instead forming complexes with other transcriptional factors (NRF1/2, PPAR, ERRs) to drive 
transcription of nuclear genes encoding mitochondrial proteins [21, 146, 147]. NRF1 and NRF2 drive 
TFAM expression which is expressed from nuclear DNA and is transported into mitochondria, driving 
transcription of 13 key enzymes from mtDNA needed for oxidative phosphorylation [21, 146, 147]. 
PPARs and ERRs mainly drive transcription of key proteins from nuclear DNA involved in oxidative 
phosphorylation [147]. 
During development, mitochondria undergo rapid biogenesis, coupled with high expression of PGC-
1α [21] and PGC-1α knockdown mice showing evidence of neuropathology and abnormal behaviour 
whilst in vitro, neurons show development changes following manipulation of PGC-1α [146]. Central 
nervous system neurons are derived from proliferative neural stem cells by neurogenesis, newly 
formed neurons grow rapidly, forming synapses and the future neuronal circuits [148]. During such 
times mitochondria biogenesis is essential for production of the large amount of ATP required; 
however, there is further evidence to suggest the presence and location of such mitochondria during 
development play a regulatory role in designing the cytoarchitecture [148]. PGC-1α has also been 
shown to play a role in formation and maintenance of synapses during development [148]. Such a role 
may be linked to neuronal requirement of an increase in energy during these processes, suggesting 
biogenesis plays an important role in development [148].  
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Biogenesis and neonatal brain injury 
Alterations in mitochondrial biogenesis may be predicted as the prerequisite fission appears to be 
upregulated immediately after neonatal HI [121]. In vitro, cerebellar granule neurons (CGNs) isolated 
from female neonatal mice were reported to have reduced mitochondrial DNA content, reduced 
expression of transcription factors required for mitochondrial biogenesis and reduced membrane 
potential and ATP. Therefore in contrast with enhanced protection of females suggested in studies of 
mitophagy, female CGNs were more susceptible to cell death [149]. In vivo, neonatal HI injury induces 
a marked upregulation of mitochondrial DNA mass and key transcription factors, which reaches a peak 
at 24h post injury [150].  
 
Mitotherapeutics – a new avenue for treating neonatal brain injury  
Given the variety of ways in which mitochondria are targeted after exposure to hypoxic-ischaemic 
injury, it is logical to explore therapies which maintain mitochondrial health, to act in synergy with 
therapeutic hypothermia. A number of therapies which impact on mitochondrial function are already 
approved for clinical trial (erythropoietin, melatonin, stem cells) and have been reviewed very recently 
as well as a number of additional suggestions of mitochondrial protein targets ([146]; table 1). 
However there are an increasing number of small molecule activators and inhibitors which are 
targeted directly to the mitochondrion which may prove invaluable as therapeutic tools (table 1). 
Selective targeting to the mitochondrion can be achieved using lipophilic cation conjugation such as 
tetra- and triphenylphosphonium (TPP) as well as mitochondria-penetrating peptides which can be 
delivered orally, intravenously, intraperitoneally or intranasally [151, 152]. However, it must be noted 
that TPP delivery is not as efficient at delivery to the brain as to peripheral organs [152]. Other delivery 
systems have been developed (gold, titanium nanoparticles etc.) which aim to circumvent 
disadvantages of liposome mediated systems such as size limitations [153]. Targeting antioxidants and 
bioactive therapeutics selectively to mitochondria is rapidly becoming an achievable goal for 
development of adjunct therapies. 
Direct modulators of mitochondrial function 
Coenzyme Q10 (CoQ10) acts as an electron acceptor to reduce the production of ROS by complex I. 
CoQ10 administration post injury was found to be neuroprotective, reducing the effects of ischaemia 
in a wide variety of rodent models including traumatic brain injury [154], middle cerebral artery 
occlusion (MCAO; [155, 156]), MCAO with hyperglycaemia [157], ischaemia in aged rodent models of 
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Alzheimer’s disease [158]. Currently there are no studies of CoQ10 in neonatal hypoxic-ischaemic 
brain injury models. 
Mitoquinone (MitoQ) is also a ubiquinone derivative conjugated to TPP which acts as an anti-oxidant 
to prevent the production of superoxide and further ROS generation. In inflammation models, MitoQ 
has been shown to suppress the production of IL-6, TNF, CXCL8/IL-8, and IL-10 in peripheral blood 
monocytes from patients with TNF-Receptor Associated Periodic Fever Syndrome (TRAPS) offering 
potential therapeutic benefit [159]. Although promising in ischaemia-reperfusion studies in peripheral 
tissues e.g. heart [160], there are limited data regarding MitoQ post-treatment in hypoxic-ischaemic 
brain injury [161]. The limited data on neonatal brain HI suggests that mitoQ is not neuroprotective in 
medium spiny neurons of the thalamus [162]. However studies in adult ischaemic injury suggests that 
intranasal delivery of plant-derived ubiquinones, plastoquinone and thymoquinone conjugated to 
rhodamine 19, may have significant neuroprotective properties post injury [152].  
Metformin is an inhibitor of mitochondrial respiration with actions on mitochondrial complex I [163, 
164]. It was recently administered after neonatal HI in rats and was found to improve performance in 
behavioural tests as well as promote oligodendrocyte survival with consequent effects on 
remyelination [165]. Metformin has been successfully used in rodent models to target inflammatory 
T cells in lupus in combination with glycolytic inhibition using 2-deoxyglucose. Metformin is also used 
to inhibit interleukin 1β (IL1β) production in LPS-induced sepsis [64] and maternal metformin 
treatment in a rat model of metabolic syndrome is beneficial in preventing foetal inflammation, a risk 
factor for perinatal HI [166].  
S1/S3QELs The mitochondria targeted antioxidant S1QELs (site IQ electron leak ) and S3QELs (site IIIQ 
electron leak) are novel compounds recently developed as selective suppressors of complex I-
dependent and complex III-dependent O2.- /H2O2 production which do not inhibit oxidative 
phosphorylation [167]. These have currently not been tested in vivo although promising results have 
been obtained after hypoxia in vitro [168] and in ischaemic reperfusion injury in perfused mouse heart 
[169]. 
Daidzein (also Daidzein sulphonate sodium) is a plant-derived polyphenol which was first reported 
as protective in cancers and inflammatory conditions. However recent studies suggest that Daidzein 
has anti-oxidant effects in rodent models of MCAO preventing ROS production, mitochondrial swelling 
and increasing antioxidant activities (superoxide dismutase, glutathione peroxidase [170-173]). 
Neither daidzein nor its derivatives have been tested in neonatal HI brain injury. 
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mDivi-1 was originally identified as a specific inhibitor of the fission mediator Drp1. However, a very 
recent study suggested that mdivi-1 is a poor inhibitor of Drp1 and rather acts as a reversible 
mitochondrial complex I inhibitor and regulator of ROS production [174]. Regardless, a number of 
studies have shown that mdivi-1 improves outcome after OGD [119, 175-178] and abrogates brain 
injury after MCAO [175], subarachnoid haemorrhage [179], transient global ischaemia [180] and 
traumatic brain injury [181].  
P110 is a peptide derived from the interaction site of Drp1 and Fis1 and acts to block the localisation 
of Drp1 to the mitochondrion [182]. P110 provided neuroprotection in cell models of Parkinson’s 
disease [182] and Huntington’s disease [183] dopaminergic neurons as well as in rodent models of 
neurodegeneration [183, 184] and myocardial infarction [185]. It has not yet been tested in neonatal 
HI brain injury.  
Conclusions and Perspectives  
The urgent unmet clinical need to provide synergistic neuroprotection alongside therapeutic 
hypothermia for neonates suffering the consequences of birth asphyxia requires novel avenues of 
drug discovery to be explored. Therapeutics which have achieved preclinical success in models of adult 
brain hypoxic-ischaemic injury cannot simply be transferred to the neonate. For a number of years we 
have understood that mitochondria act as the target of the injury response, and the pathway in which 
MOMP in the immature brain leads to apoptosis and necroptosis during the secondary phase of injury 
has been well characterised. Pharmacological tools developed from this research (e.g. the caspase-
2/3 inhibitor TRP601 [47]) have already provided proof-of-concept data suggesting that intervention 
post injury can be efficacious. As we come to understand more about fission, fusion, mitophagy and 
biogenesis of the mitochondrion and how this lifecycle becomes adversely affected by HI injury, we 
are provided with additional therapeutic targets. Emerging data regarding sex-specific differences in 
fission, mitophagy and biogenesis responses require us to be rigorous in preclinical testing of new 
therapeutics targeting these points. Direct targeting of mitochondria is now becoming a reality and a 
wealth of small molecule modulators offers the potential sensitivity and specificity required to 
ameliorate the lifelong impact of hypoxic ischaemic brain injury in these vulnerable infants.  
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Table 1: Mitochondrial therapeutics with potential to ameliorate neonatal HI brain injury 
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Figure 1: Neonatal HI injury results in mitochondrial outer membrane permeabilisation (MOMP) and 
cell death. Neonatal HI induces mitochondrial accumulation of calcium, increased production of 
reactive oxygen and reactive nitrogen species. Changes in Bcl-2 family proteins induce Bax-dependent 
MOMP leading to the release of cytochrome c (cyt c) and apoptosis-inducing factor (AIF). The 
apoptosome is formed of cyt c, APAF-1 and caspase-9 which leads to caspase-3 activation, caspase-
activated DNases (CAD) and DNA degradation. AIF forms a complex with cyclophilin A (CyA) which 
translocates to the nucleus and induces chromatinolysis and apoptotic cell death. B) Concomitantly, 
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inflammatory microglia and astroglia will release death receptor ligands (FasL, TWEAK, TRAIL, LPS) 
leading to the activation of death receptors, which in turn contribute to the induction of apoptosis. 
Figure 2: Mitochondrial dynamics, mitophagy and biogenesis. Fission, fusion, mitophagy and 
biogenesis are balanced to ensure efficient ATP production through fusion (with minimal generation 
of ROS/RNS) and degradation of damaged mitochondria (through fission and mitophagy). Biogenesis 
restores fissioned mitochondria lost to mitophagy. During mitophagy, damaged mitochondria are 
recruited to the phagophore through LC3B and engulfed into the autophagosome. Fusion with a 
lysosome results in degradation of the mitochondrion within the autolysosome. Key proteins for each 
stage are shown together with the regulation of Drp1; Ser 637 phosphorylation keeps Drp1 in the 
cytosol, whereas dephosphorylation by calcineurin or PP2A and rephosphorylation at Ser616 results 
in its mitochondrial location. 
Figure 3: Mechanisms of mitophagy. A) On mitochondrial depolarisation, PINK1 degradation is 
prevented. PINK1 thus accumulates at the OMM where it phosphorylates ubiquitin present on 
proteins of the OMM. To amplify this response, PINK1 also phosphorylates the ubiquitin-like domain 
of E3 ubiquitin ligase Parkin, resulting in its migration to the mitochondrion and its recruitment of 
ubiquitin, providing more substrates for PINK1 phosphorylation. Phosphorylated Ub acts to recruit 
autophagy receptors such as OPTN, NDP52 and p62/SQSTM which bind to phagophore-located LC3B 
and enable the dysfunctional mitochondria to be engulfed into an autophagosome where it is 
subsequently degraded on fusion with a lysosome. B) BNIP3 and Nix are mitochondria-located 
transmembrane proteins stabilised in response to hypoxia. Both are capable of binding LC3B directly 
and recruiting the mitochondrion to the autophagosome. C) Dephosphorylation of FUNDC1 by PGAM5 
in response to hypoxia reveals its canonical LC3B binding site through which it can bind LC3B directly 
and recruit the phagophore membrane, enabling mitophagy. 
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